Virtus Advisers LLC Makes New $888,000 Investment in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Virtus Advisers LLC has invested $888,000 in Prestige Consumer Healthcare Inc. (NYSE:PBH), acquiring 10,324 shares, which now constitutes about 1.2% of its portfolio.
• Prestige Consumer Healthcare reported earnings of $0.95 per share for the last quarter, which missed analysts' estimates of $1.01, along with a revenue of $249.53 million, down 6.6% from the previous year.
• Several hedge funds, including Kayne Anderson Rudnick and GAMMA Investing LLC, significantly increased their stakes in Prestige Consumer Healthcare recently, contributing to over 99% institutional ownership in the company.

Virtus Advisers LLC bought a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 10,324 shares of the company's stock, valued at approximately $888,000. Prestige Consumer Healthcare accounts for about 1.2% of Virtus Advisers LLC's holdings, making the stock its 16th biggest holding.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Kayne Anderson Rudnick Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $84,932,000. Invesco Ltd. increased its stake in shares of Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock valued at $113,635,000 after purchasing an additional 261,537 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Prestige Consumer Healthcare by 1,073.3% during the fourth quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company's stock valued at $15,923,000 after purchasing an additional 186,524 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Prestige Consumer Healthcare by 11,580.3% during the first quarter. GAMMA Investing LLC now owns 161,538 shares of the company's stock valued at $13,887,000 after purchasing an additional 160,155 shares in the last quarter. Finally, Neumeier Poma Investment Counsel LLC bought a new position in shares of Prestige Consumer Healthcare during the first quarter valued at approximately $8,713,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Wall Street Zen cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Stock Performance

Shares of PBH traded up $0.41 during trading hours on Thursday, hitting $67.37. The stock had a trading volume of 676,013 shares, compared to its average volume of 602,764. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. Prestige Consumer Healthcare Inc. has a 12 month low of $62.95 and a 12 month high of $90.04. The firm has a market capitalization of $3.32 billion, a PE ratio of 15.81, a PEG ratio of 2.11 and a beta of 0.43. The stock has a fifty day moving average price of $73.94 and a 200 day moving average price of $80.70.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.06). The firm had revenue of $249.53 million during the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business's revenue was down 6.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.